FTRE vs LH
FTRE: Fortrea is a dedicated global CRO focused on clinical trial execution and commercialization services to help biopharmaceutical companies bring new therapies to market. LH: Labcorp is a leading global life sciences company providing essential clinical diagnostic testing and drug development services to the healthcare industry.
Side-by-side fundamentals
| Metric | FTRE | LH | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $19.05 | $313.96 | |
| Market cap as of 2026-08-06 | $1.8B | $25.7B | |
| P/E as of 2026-08-06 | n/a | 25.34 | |
| PEG as of 2026-08-06 | 0.45 | 3.11 | FTRE lower |
| Net margin as of 2026-08-06 | -3.2% | +7.0% | LH higher |
| Gross margin as of 2026-08-06 | +19.3% | +28.9% | LH higher |
| Operating margin as of 2026-08-06 | -0.4% | +10.4% | LH higher |
| ROE as of 2026-08-06 | -15.5% | +11.6% | LH higher |
| ROA as of 2026-08-06 | -3.1% | +5.4% | LH higher |
| Debt / equity as of 2026-08-06 | 2.01 | 0.69 | LH lower |
| Revenue growth (YoY) as of 2026-08-06 | -2.1% | +6.4% | LH higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | +5.6% | LH higher |
| Dividend yield as of 2026-08-06 | n/a | +0.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 4 | |
| Beta as of 2026-08-06 | 1.99 | 0.86 | |
| 1-year return as of 2026-08-05 close | +190.4% | +19.2% | FTRE higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.